Veraxa Biotech AG VRXA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -89.32%
- 1 year
- -89.14%
- Open
- 1.18
- Prev close
- 1.13
- Mkt cap
- 161.20M
- Vol
- 261.43K
- Avg vol
- 256.26K
- EPS
- -0.57
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.25
News
2 weeks ago globenewswire.com
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.
3 weeks ago barrons.com
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.'
3 weeks ago globenewswire.com
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs.
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies…
1 month ago globenewswire.com
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today…
-
2 months ago benzinga.com
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a company
3 months ago globenewswire.com
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent…
-
3 months ago benzinga.com
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
3 months ago globenewswire.com
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of…
3 months ago globenewswire.com
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an…
3 months ago globenewswire.com
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph…
-
3 months ago benzinga.com
VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA))), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the
3 months ago globenewswire.com
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from…
-
3 months ago benzinga.com
VERAXA Biotech Partners With AI-Driven Computational R&D Partner Ardigen To Support Its Growing BiTAC Pipeline Of T Cell Engagers And Antibody Drug Conjugates
The collaboration is another milestone in VEREXA’s mission to integrate AI into its research and development, with the long-term goal to achieve success rates in drug development that exceed industry…
3 months ago globenewswire.com
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
ZURICH, SWITZERLAND - July 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S. A. , an…
3 months ago benzinga.com
FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday
U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and Q32 Bio among stocks to watch. More premarket coverage at Benzinga.
-
3 months ago benzinga.com
VERAXA Biotech Appoints Carl Von Halem As Interim CFO, Succeeding Torsten Bürgermeister
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds…
3 months ago globenewswire.com
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
ZURICH, SWITZERLAND - July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim…
3 months ago benzinga.com
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…
-
3 months ago benzinga.com
VERAXA Biotech Channels Investment Into BiTAC Portfolio, Eyes BiTAC-TCE Candidate VXA-102 IND/CTA-Ready By 2028
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update."In the first six months of 2026, we have made…
3 months ago globenewswire.com
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals…
-
4 months ago benzinga.com
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
-
4 months ago benzinga.com
Veraxa Biotech Initiated Cell Line Development For Its Lead BiTAC T-cell Engager Program
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC® T-cell engager…
4 months ago globenewswire.com
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
ZURICH, SWITZERLAND - July 02, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for…
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…
-
4 months ago benzinga.com
VERAXA Biotech Moves Into Additional Laboratory Space At Existing R&D Site In Heidelberg, Germany, To Support Team Growth And Infrastructure Build‑Out
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D…
4 months ago globenewswire.com
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
4 months ago globenewswire.com
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro…
4 months ago benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
4 months ago benzinga.com
Why La-Z-Boy Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expected results and announcing a $300 million share buyback.
4 months ago benzinga.com
Crude Oil Down Over 3%; US Consumer Sentiment Rises In June
Dow Jones up 0.56%, NASDAQ up 0.08%, S&P 500 up 0.32%. Materials shares rise 1.7%, consumer discretionary down 1.3%. University of Michigan's consumer sentiment index beats estimates. Oil down 3.3%,…
-
4 months ago benzinga.com
VERAXA Biotech And Voyager Acquisition Complete Business Combination; On June 11, 2026, VERAXA Will Commence Trading Its Shares Under The Symbol "VRXA"
Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel…